MD Biopharm Co. Ltd. has described protein-glutamine γ-glutamyltransferase 2 (TGM2) inhibitors reported to be useful for the treatment of cancer, celiac disease, neurological, inflammatory and cardiovascular disorders.
Chengdu Baiyu Pharmaceutical Co Ltd. has divulged poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors with improved blood-brain barrier penetration ability and reported to be useful for the treatment of cancer.
Insilico Medicine IP Ltd. has identified small-molecule inhibitors of ubiquitin carboxyl-terminal hydrolase 1 (USP1) reported to be useful for the treatment of cancer.
Positive data from two studies treating early breast cancer with CDK4/6 inhibitors presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago showed progress is helping patients live longer. The two treatments and companies, Novartis AG and Eli Lilly and Co., are nearly head-to-head competitors in the niche indication.
Insilico Medicine IP Ltd. has identified small-molecule inhibitors of ubiquitin carboxyl-terminal hydrolase 1 (USP1) reported to be useful for the treatment of cancer.
By interfering with mitochondrial plasticity, researchers have succeeded in attenuating brain metastases of HER2-expressing breast tumors. The authors wrote that their findings “highlight targeting mitochondrial dynamics is a viable therapeutic opportunity to limit both brain tumors and metastasis.”
Imaginab Inc. has selected and advanced into IND-enabling studies IAB-56, a minibody designed to target the αvβ6 integrin for use as Lu-177 radiopharmaceutical therapy in solid tumors. In parallel, the DLL3-targeting program, IAB-57, will further assess several leads in the coming quarter prior to initiation of IND-enabling studies later this year.
